Skip to content
India Japan Kaizen
← All stories
🏭

Noida's Medical Device Park Misses Its Own Deadline

November 8, 2026 · by India Japan Kaizen Team

India Japan Kaizen — Health & Beauty Bridge Series, Part 7

Part 6 closed with one embarrassing catch-up and four threads still dangling. The catch-up: UP's own board had quietly cleared 500 acres in Sectors 13 and 14 for a regional medical hub near Jewar Airport back in August 2026 — two months before this series went looking for an address and found one it should have caught sooner. The four threads: no official word from the AYUSH Ministry or the Health Ministry that Jewar, or anywhere else, is one of the Union Budget's five promised medical-tourism hubs; no named Japanese tenant at YEIDA's Medical Device Park despite May's Medical Excellence Japan agreement; no funded project under the ICMR-DST-AMED research pact signed the same month; and no Japanese beauty or hospital operator's inbound-language plan reaching past English and Chinese into Hindi or South Asia. A week spent back at those four found something sharper than a missing name on the device-park side — a missed deadline — plus two stories from directions this series hasn't looked in before: Japan's own government is quietly tightening the welcome mat for the same kind of medical travelers it's courting, and a second major Japanese cosmetics group may be about to do in India what Kao and Kosé have so far avoided doing.

A Missed Deadline, Not Just a Missing Tenant

Start with the device park, because what moved there this time wasn't the tenant list — it was the calendar. The Centre set March 2026 as the deadline for completing YEIDA's Medical Device Park when it approved the project; a report from early January 2026 said YEIDA had instead asked for a one-year extension, pushing completion to March 2027, and blamed the slippage on tender delays and pending approvals rather than demand. The funding structure attached to that deadline is its own small story: the Centre committed a ₹100 crore grant for the park, of which roughly ₹60 crore has been released in two installments, with the final tranche conditioned on YEIDA first spending at least ₹3 crore of what it already has. None of the boosterish numbers Part 6 cited — the twelve companies and roughly ₹500 crore in fresh commitments from July's YEIDA MedTech Investors' Meet, the August board approval of an FDA-ASCA-aligned testing facility — change the fact that, by the government's own original timeline, the park is already overdue. And the allotment list still hasn't grown a Japanese name: TI Medical, an Indian device maker with an 11-acre plot, remains the closest thing to a confirmed anchor tenant the park has, more than a year after Medical Excellence Japan signed its framework agreement with YEIDA in May.

Japan Is Tightening the Door It's Also Trying to Open Wider

The series has spent six parts watching India build medical-tourism infrastructure aimed partly at Japan. It hasn't yet looked at what Japan itself is doing with its own inbound patients — and as of this year, the answer is two things at once. On one side, Japan's government is pitching itself as a premium medical-travel destination: coverage from early November 2026 describes officials planning to compile findings from an ongoing review of the sector as soon as next fiscal year, built around high-end draws like heavy-ion radiotherapy centers at Gunma and Yamagata universities and comprehensive "Ningen Dock" health screenings marketed specifically to wealthy overseas visitors. On the other side, the same government is restricting who gets to use that system on favorable terms: a January 2026 action plan committed to studying a requirement that foreign visitors hold private medical insurance before entering the country, a response to a health ministry survey that found unpaid medical bills from foreign patients; a Cabinet Secretariat progress report from June 2026 shows the threshold for flagging an unpaid bill as a problem case was cut to ¥10,000 starting in April 2026, meaning smaller unpaid amounts now count against a visitor's record. Neither the insurance requirement nor a hard entry rule is in force yet — it remains, in the government's own language, "under study" — but the direction matters for this series: whatever regime eventually emerges will apply to any Indian patient Part 5 and Part 6's medical-tourism hubs eventually send toward Japan, not just the reverse flow this series has tracked so far.

A Second Japanese Beauty Giant Quietly Eyes Indian Manufacturing

On the consumer side, Part 1 named Kosé and SK-II as brands pushing into India's premium retail, and Part 2 covered Kao's distribution deal for Bioré — but all three of those are ways of selling into India, not building inside it. Shiseido, Japan's largest cosmetics company, has reportedly been considering something closer to the device-factory pattern Part 1 found on the medical side: local manufacturing. Reporting that first surfaced in October 2025, and was still being repeated in Japanese trade press as recently as July 2026, says the company is evaluating Indian production to offset the roughly 20% basic import duty, 18% GST, and 10% social-welfare surcharge it currently absorbs by importing its entire Indian product range; India country head Sanjay Sharma has said local output would bring the company "inherent advantages." A year on from the first reports, though, nobody has named a site, a capital figure, or a construction timeline — which makes this a live rumor worth tracking, not yet a deal worth filing next to Kao's.

Everything Else, Exactly Where Part 6 Left It

The remaining threads haven't moved. Neither the AYUSH Ministry nor the Health Ministry has said Jewar, or any other site, is one of the Budget's five regional hubs — that link still exists only in UP's own framing. AMED's public calls-for-proposals page still lists nothing involving ICMR, more than six months after the May memorandum of cooperation. FICCI has not announced a ninth Advantage Healthcare India; the Services Export Promotion Council's most recent Sanjeevani was its 7-9 September edition at Bharat Mandapam, now two months in the past, with no next edition on the calendar. And SBC Medical, the Shonan Beauty Clinic operator Parts 4 through 6 have tracked, still names Singapore, Thailand, and the U.S. as its international priorities — not India, Hindi, or South Asia.

What's Still Missing

  • Official confirmation that Jewar — or any site — is one of the Union Budget's five regional medical-tourism hubs. UP's own announcements make the link; neither the AYUSH Ministry nor the Health Ministry has.
  • A ruling on YEIDA's requested one-year extension for the Medical Device Park, and a named Japanese tenant among its allottees, a year after Medical Excellence Japan's framework agreement.
  • A finished rule, not a study, on Japan's proposed insurance-before-entry requirement for foreign patients — the regime that will eventually govern any Indian medical traveler this series' hubs send toward Japan.
  • A confirmed site, investment figure, or timeline for Shiseido's reported Indian manufacturing plan, more than a year after it first surfaced.
  • Dates for Advantage Healthcare India's ninth edition or Sanjeevani's next edition, and any Japanese beauty or hospital operator's inbound-language plan that reaches Hindi or South Asia rather than stopping at English and Chinese.

If you work in medtech investment, industrial site selection, cross-border healthcare policy, or language services for aesthetic and wellness clinics — get in touch. Closing the gap between what gets announced and what actually gets built is exactly the kind of work India Japan Kaizen exists to do.

This is Part 7 of India Japan Kaizen's Health & Beauty Bridge Series, publishing weekly. Part 8 will check whether the Centre has ruled on YEIDA's extension request, whether a single Japanese company's name has finally attached to a plot at the Medical Device Park, and whether Japan's insurance-before-entry study has hardened into an actual rule.

More from this series

View more →
🩺

November 15, 2026

Big Names Circle Noida's Device Park, Still Not Japan's

GE Healthcare, Philips, and Panacea are now circling YEIDA's device park, Japan's insurance study gets a 2028 system to attach to, and Hindi still isn't in the room. Part 8.

Read more →
📍

November 1, 2026

An Address Surfaces for India's Medical-Tourism Hub

YEIDA quietly gave the Budget's health hub an address in August — before Part 5 even looked. The device park, research pact, and beauty side's Hindi gap still haven't moved. Part 6.

Read more →
🏗️

October 25, 2026

Where India-Japan Health Ties Are Actually Moving

Part 4's two tracked questions are still open, but a Japanese medtech MoU, a Budget hub blueprint, and a beauty clinic's language rollout show where this relationship is actually moving. Part 5.

Read more →
🛡️

October 18, 2026

A New Health Pact, But the Insurance Gap Stays

India and Japan signed a health-research pact and Galaxy Health launched travel cover — but the inbound medical-tourism insurance product Goyal asked for in September still doesn't exist. Part 4.

Read more →
🌿

October 4, 2026

India Wants 10 Million Medical Tourists. Where's Japan?

India just set a 10-million-patient medical-tourism target while Japan's own inbound numbers stay tiny. Who's actually building the bridge, and the real state of Kampo-Ayurveda. Part 3.

Read more →
💉

September 27, 2026

A Vaccine, a Caregiver Visa, and Bioré's India Debut

A Japanese vaccine maker is transferring tech to Serum Institute, Kao picked its India partner for Bioré, and a caregiver pipeline has a mandate. Part 2 of our Health & Beauty Bridge Series.

Read more →
🧴

September 20, 2026

Pharma, Med-Tech, J-Beauty, and Ayurveda: India-Japan's Wellness Bridge

India's pharma exports to Japan are barely a rounding error, even as Japanese med-tech giants build factories across India. Meanwhile J-beauty is entering India and Ayurveda is entering Japan, at the same time. Part 1 of our weekly Health & Beauty Bridge Series.

Read more →

Explore other weekly series